| Jessica Reichbind, | |
|
6 Main St, Durham, CT 06422-2130 | |
| (860) 358-5020 | |
| (860) 358-8652 |
| Full Name | Jessica Reichbind |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 6 Main St, Durham, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417367657 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 52253 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Middlesex Hospital | Middletown, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mhs Primary Care, Inc | 4082507371 | 143 |
News Archive
Orexo AB announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral, Orexo´s product for the treatment of breakthrough cancer pain.
EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.
Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.
Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
| Entity Name | Mhs Primary Care, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740666312 PECOS PAC ID: 4082507371 Enrollment ID: O20040202000945 |
News Archive
Orexo AB announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral, Orexo´s product for the treatment of breakthrough cancer pain.
EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.
Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.
Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Reichbind, 1351 Washington Blvd, Stamford, CT 06902-2419 Ph: (203) 276-1000 | Jessica Reichbind, 6 Main St, Durham, CT 06422-2130 Ph: (860) 358-5020 |
News Archive
Orexo AB announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral, Orexo´s product for the treatment of breakthrough cancer pain.
EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.
Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.
Targeted Genetics Corporation announced that its partner, Celladon Corporation, today presented 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrating significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.
› Verified 8 days ago
Dr. Theodore Bruno, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12 Pleasant Ter, Durham, CT 06422 Phone: 860-888-2700 | |
Nazmiye Esra Hatiboglu, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6 Main Street, Durham, CT 06422 Phone: 860-349-1058 Fax: 860-358-8652 | |
Bradford W Wilkinson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6 Main St, Durham, CT 06422 Phone: 860-349-1058 Fax: 860-358-8652 | |
John M Carbone, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6 Main St, Durham, CT 06422 Phone: 860-349-1058 Fax: 860-358-8652 | |
Marc Roy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6 Main St, Durham, CT 06422 Phone: 603-585-0208 Fax: 860-358-8652 |